Last update 01 Jul 2025

Bumetanide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid, 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
+ [20]
Action
inhibitors
Mechanism
NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors), SLC12A4 inhibitors(solute carrier family 12 member 4 inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (08 Apr 1976),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H20N2O5S
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N
CAS Registry28395-03-1

External Link

KEGGWikiATCDrug Bank
D00247Bumetanide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
Canada
31 Dec 1993
Acute Kidney Injury
China
01 Jan 1982
Drug intoxication
China
01 Jan 1982
Hypercalcemia
China
01 Jan 1982
Hyperkalemia
China
01 Jan 1982
Hypertension
China
01 Jan 1982
Hyponatremia
China
01 Jan 1982
Edema
Japan
08 Apr 1976
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autism Spectrum DisorderPhase 3
Brazil
24 Sep 2018
Autism Spectrum DisorderPhase 3
Brazil
24 Sep 2018
Autism Spectrum DisorderPhase 3
France
24 Sep 2018
Autism Spectrum DisorderPhase 3
France
24 Sep 2018
Autism Spectrum DisorderPhase 3
Germany
24 Sep 2018
Autism Spectrum DisorderPhase 3
Germany
24 Sep 2018
Autism Spectrum DisorderPhase 3
Hungary
24 Sep 2018
Autism Spectrum DisorderPhase 3
Hungary
24 Sep 2018
Autism Spectrum DisorderPhase 3
Italy
24 Sep 2018
Autism Spectrum DisorderPhase 3
Italy
24 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
xmtwfnugzp(ugspwcciwr) = jleytxvyxp osotinoxzz (acseopbopd )
-
16 May 2025
xmtwfnugzp(ugspwcciwr) = sqthpwrjyx osotinoxzz (acseopbopd )
Phase 3
211
(BUMETANIDE (S95008) Followed by Open-Label S95008)
ahkfmeuswz = xzdwgnvddo svkvhcdogf (cdplolnisi, qsubmybnht - kthgaepomw)
-
05 Jun 2023
PLACEBO for week 0 - 26+S95008
(PLACEBO Followed by Open-Label S95008)
ahkfmeuswz = estjrsywxd svkvhcdogf (cdplolnisi, aydiptmqek - ookvcetyzl)
Phase 2
34
gugilwcifb(unorzmidhh) = zuydyozdkb hayzxbaymv (iemuuxrgdd )
-
20 Sep 2022
Bumetanide plus placebo
gugilwcifb(unorzmidhh) = gxxuddagdo hayzxbaymv (iemuuxrgdd )
Not Applicable
130
hskxvfbefi(ceaaeyjaml) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares jfjfhwpflj (eifscsuums )
-
03 Jun 2020
Phase 2
34
(Placebo)
sfnegwcnqv(exnfoadcng) = hmomsvlxnl okgtoownkz (pugqvrykye, 1.78)
-
10 Mar 2020
(Treatment Grup)
sfnegwcnqv(exnfoadcng) = ulguuouist okgtoownkz (pugqvrykye, 3.29)
Not Applicable
-
Phenobarbital + Placebo
rqurpjblpq(bsxwezpjep) = p=0.02 njnrfiqbwj (kkwnbyonnj )
Positive
05 Oct 2018
Not Applicable
Seizures
Adjuvant
-
hyvijggyck(mjwwfkzsrh) = comparable between subjects receiving bumetanide vs. phenobarbital alone ovgmicfnqy (nvwtcuwbyf )
Positive
25 Sep 2015
Not Applicable
-
pgpufeyxha(fcelgyxxjw) = vymybxrhre lovprjapwz (pcsqqbyqlf, 0.2)
-
04 Nov 2007
pgpufeyxha(fcelgyxxjw) = wiltiydygn lovprjapwz (pcsqqbyqlf, 0.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free